Related Experiment Video
Updated: Apr 6, 2026
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Targeted radionuclide therapies for pancreatic cancer
M Shah1, R Da Silva1, C Gravekamp2
1Departments of Radiology, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract:
Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides, which bind to the receptors overexpressed by cancer cells and radiolabeled antibodies to tumor-specific antigens provide a viable alternative to chemotherapy and external beam radiation of metastatic cancers. Multiple clinical trials of targeted radionuclide therapy of pancreatic cancer have been performed in the last decade and demonstrated safety and potential efficacy of radionuclide therapy for treatment of this formidable disease. Although a lot of progress has been made in treatment of pancreatic neuroendocrine tumors with radiolabeled (90)Y and (177)Lu somatostatin peptide analogs, pancreatic adenocarcinomas remain a major challenge. Novel approaches such as peptides and antibodies radiolabeled with alpha emitters, pre-targeting, bispecific antibodies and biological therapy based on the radioactive tumorlytic bacteria might offer a potential breakthrough in treatment of pancreatic adenocarcinomas.
Insights
Pancreatic cancer remains challenging, but targeted radionuclide therapies show promise. Novel approaches like alpha emitters and bispecific antibodies may offer breakthroughs for pancreatic adenocarcinomas.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Pancreatic malignancies are aggressive, leading causes of cancer death with poor prognosis.
- Early detection is difficult, often diagnosed at metastatic stages.
- Current treatments have limited efficacy for pancreatic adenocarcinomas.
Purpose of the Study:
- To review the progress and challenges in targeted radionuclide therapy for pancreatic cancer.
- To explore novel therapeutic strategies for pancreatic adenocarcinomas.
Main Methods:
- Review of clinical trials on targeted radionuclide therapy for pancreatic cancer.
- Analysis of radiolabeled peptides and antibodies targeting cancer cells.
- Evaluation of emerging therapeutic modalities.
Main Results:
- Targeted radionuclide therapy has demonstrated safety and potential efficacy for pancreatic cancer.
- Progress is notable in pancreatic neuroendocrine tumors using somatostatin analogs.
- Pancreatic adenocarcinomas remain a significant challenge.
Conclusions:
- Targeted radionuclide therapy is a viable alternative to conventional treatments.
- Novel approaches including alpha emitters, pre-targeting, and bispecific antibodies are promising for pancreatic adenocarcinomas.
- Further research into innovative radionuclide therapies is crucial for improving patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies